`Filed: November 23, 2015
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
`INNOPHARMA INC., INNOPHARMA LLC,
`MYLAN PHARMACEUTICALS INC., and MYLAN INC.,
`Petitioners
`v.
`
`SENJU PHARMACEUTICAL CO., LTD.,
`Patent Owner
`_________________
`Case IPR2016-00089
`U.S. Patent 8,754,131
`_________________
`
`PATENT OWNER’S MANDATORY NOTICES
` PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C _F.R. § 42.8(a)(2), Patent Owner Senju Pharmaceutical C0.,
`
`Ltd. (“Senju”) hereby submits the following mandatory notices in connection with
`
`Case IPR2016-00089
`
`U.S. Patent 8,754,131
`
`this proceeding.
`
`I.
`
`SENJU’S POWER OF ATTORNEY
`
`A Power of Attorney appointing lead and back—up counsel is being filed
`
`concurrently with these Notices.
`
`II.
`
`SENJU’S MANDATORY NOTICES
`
`(a) 37 C.F.R. § 42.8(b)(1): Real Party—in—Interest
`
`The real pa1ty—in—interest for the Patent Owner is Senju Pharmaceutical C0,,
`
`Ltd. Other real parties-in-interest include Bausch & Lomb Inc., and Bausch &
`
`Lomb Phanna Holdings Corp.
`
`(b) Related Matters
`
`1. Judicial
`
`The patent challenged here, U.S. Patent 8,754,131 (“the ’13l patent”), has
`
`been asserted in the following litigations:
`
`Case Caption
`
`Ltd. and Lu in Pharms., Inc.
`
`Senju Pharm. Co. Ltd., Bausch & Lomb, Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Lupin,
`
`
`
`Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Metrics,
`Inc., Coastal Pharms., Inc., Mayne Pharma Group
`Ltd., and Mayne Pharma (USA), Inc.
`Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Metrics,
`Inc., Coastal Pharms., Inc., Mayne Pharma Group
`Ltd., and Mayne Pharma (USA), Inc.
`Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Metrics,
`Inc., Coastal Pharms., Inc., Mayne Pharma Group
`Ltd., and Mayne Pharma (USA), Inc.
`Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and
`Bausch & Lomb Pharma Holdings Corp. v.
`Innopharma Licensing, Inc., Innopharma Licensing,
`LLC, Innopharma, Inc., and Innopharma LLC
`Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Apotex
`Inc. and Apotex Corp.
`Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Paddock
`Laboratories, LLC, L. Perrigo Co., and Perrigo Co.
`Senju Pharmaceutical Co. Ltd., Bausch & Lomb Inc.
`and Bausch & Lomb Pharma Holdings Corp. v.
`Paddock Labs., LLC, L. Perrigo Company, and
`Perrigo Co.
`Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and
`Bausch & Lomb Pharma Holdings Corp. v.
`InnoPharma Licensing, Inc., Innopharma Licensing,
`LLC, Innopharma, Inc., Innopharma, LLC, Mylan
`Pharms., Inc., and Mylan Inc.
`Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and
`Bausch & Lomb Pharma Holdings Corp. v. Watson
`Labs., Inc., Actavis, Inc. and Actavis Pharma, Inc.
`
`There are four other related patents currently involved in parallel district
`
`D.N.J. Nov. 3,
`2014
`
`D.N.J. Jan. 16,
`2015
`
`D.N.J. Jan. 16,
`2015
`
`D.Del. Jan. 26,
`2015
`
`D.N.J. May 8,
`2015
`
`D.N.J. Jul. 16,
`2015
`
`Case IPR2016-00089
`U.S. Patent 8,754,131
`
`D.N.J.
`
`June
`20,
`2014
`
`D.N.J. Aug. 7,
`2014
`
`E.D.N
`.C.
`
`Aug. 8,
`2014
`
`1:14-
`cv-
`03962
`
`1:14-
`cv-
`04964
`
`4:14-
`cv-
`00141
`
`1:14-
`cv-
`06893
`1:15-
`cv-
`00336
`1:15-
`cv-
`00337
`1:15-
`cv-
`00087
`
`1:15-
`cv-
`03240
`
`1:15-
`cv-
`05591
`
`court proceedings, U.S. Patents Nos. 8,129,431 (“the ’431 patent”), 8,669,290
`
`
`
`3
`
`
`
`Case IPR2016-00089
`
`U.S. Patent 8,754,131
`
`(“the ’290 patent”), 8,871,813 (“the ’813 patent”), and 8,927,606 (“the ’606
`
`patent”). As the Patent Owner reads 37 C.F.R. §42.8, Patent Owner is not
`
`required to individually identify these proceedings, but if the Board prefers them
`
`identified, Patent Owner will do so.
`
`2. Administrative
`
`Petitioner filed concurrently with this petition two other petitions for inter
`
`partes review: (1) IPR20l6—00090 of the ’813 patent, and (2) IPR20l6—0009l of
`
`the ’606 patent. Patent Owner identifies additional administrative matters related
`
`to this patent family:
`
`Case Caption
`Metrics, Inc. v. Mayne Pharma, and Johnson
`Matthey, Inc. v.
`Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and
`Bausch
`
`& Lomb Pharma Holdin s Cor .
`
`Metrics, Inc. v. Mayne Pharma, and Johnson
`Matthey, Inc. v.
`Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and
`Bausch
`
`& Lomb Pharma Holdin s Cor
`
`.
`
`Innopharma Licensing, Inc., Innopharma
`Licensing, LLC, Innopharma, Inc., Innopharma
`LLC', Mylan Pharm. Inc., and Mylan Inc. v. Senju
`Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch
`
`& Lomb Pharma Holdin s Cor .
`
`Innopharma Licensing, Inc., Innopharma
`Licensing, LLC, Innopharma, Inc., Innopharma
`LLC, Mylan Pharm. Inc., and Mylan Inc. v. Senju
`Pharm. C0., Ltd, Bausch & Lomb, Inc., and Bausch
`
`& Lomb Pharma Holdings Corp.
`
`Patent
`IPR N0.
`IPR2014- 8,129,431
`01041
`
`IPR2014- 8,669,290
`01043
`
`Filed
`June
`26,
`2014
`
`June
`26,
`2014
`
`IPR2015- 8,129,431 Mar.
`00903
`19,
`2015
`
`IPR2015- 8,669,290 Mar.
`00902
`19,
`2015
`
`
`
`Lupin Ltd. and Lupin Pharm. Inc. v.
`Senju Pharm. C0,, Ltd,
`
`Case IPR2016-00089
`
`U.S. Patent 8,754,131
`
`IPR20l5— 8,669,290 April
`01099
`23,
`2015
`
`Lupin Ltd. and Lupin Pharm. Inc. v.
`Senju Pharm. C0,, Ltd,
`
`Lupin Ltd. and Lupin Pharm. Inc. v.
`Senju Pharm. C0,, Ltd,
`
`Lupin Ltd. and Lupin Pharm. Inc. v.
`Senju Pharm. C0,, Ltd,
`
`IPR20l5— 8,754,131 April
`01097
`23,
`2015
`
`IPR20 1 5- 8,871 ,8] 3 April
`01105
`23,
`2015
`
`IPR20l5— 8,927,606 April
`01100
`23,
`2015
`
`
`
`Lupin Ltd. and Lupin Pharm. Inc. v.
`Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and
`Bausch & Lomb Pharma Holdins C01 .
`
`IPR20l5— 8,129,431
`01871
`
`Sept.
`9,
`2015
`
`(b) 37 C.F.R. § 42.8(b)(3) and (4): Lead and Back-Up Counsel, and
`Service Information
`
`Senju designates the following counsel to transact all business in the United
`
`States Patent & Trademark Office associated with the above—captioned proceeding.
`
`Lead Counsel
`
`Back-Up Counsel
`
`Bryan C. Diner (Reg. No. 32,409)
`Finnegan, Henderson, Farabow,
`Garrett & Durmer, LLP
`901 New York Avenue, NW
`
`Washington, DC 20001-4413
`Phone: (202) 408-41 16
`Fax: (202) 408-4400
`Email: Bryan.Diner@finnegan.com
`
`Justin J. Hasford
`(Reg. No. 62,180)
`Finnegan, Henderson, Farabow,
`Garrett & Durmer, LLP
`
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Phone: (202) 408-4175
`Fax: (202)408-4400
`Email: Justin.Hasford@finnegan.com
`
`Joshua L. Goldberg
`(Reg. No. 59,369)
`Finnegan, Henderson, Farabow,
`Garrett & Durmer, LLP
`
`
`
`Case IPR2016-00089
`U.S. Patent 8,754,131
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Phone: (202) 408-6092
`Fax: (202) 408-4400
`Email: Joshua.Goldberg@finnegan.com
`
`
`
`
`
`Please address all correspondence regarding this proceeding to lead and
`
`back-up counsel. Senju also consents to electronic service by email.
`
`Respectfully submitted,
`
`
`
`By: /Bryan C. Diner/
`Bryan C. Diner, Lead Counsel
`Reg. No. 32,409
`
`Counsel for Patent Owner
`
`
`
`
`
`Dated: November 23, 2015
`
`
`
`6
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2016-00089
`U.S. Patent 8,754,131
`
`The undersigned hereby certifies that a copy of the foregoing Patent
`
`Owner’s Mandatory Notices was served on November 23, 2015, via email
`
`directed to counsel of record for the Petitioner at the following:
`
`Jitendra Malik
`jitty.malik@alston.com
`
`Hidetada James Abe
`james.abe@alston.com
`
`Lance Soderstrom
`lance.soderstrom@alston.com
`
`
`Date: November 23, 2015
`
`/Bradley J. Moore/
`Bradley J. Moore
`Litigation Clerk
`
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`
`
`
`7